Rein Therapeutics (RNTX), formerly Aileron Therapeutics(ALRN), announced on Friday its rebranding to reflect its focus on developing therapies for orphan pulmonary and fibrosis indications.
The name change aligns with the company's mission to address unmet medical needs in fibrotic diseases.
Starting January 13, 2025, the company's common stock will begin trading under the new Nasdaq ticker symbol "RNTX."
The company's lead candidate, LTI-03, a Caveolin-1 related peptide, is set to enter a Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
In November 2024, Rein announced positive topline data from the Phase 1b trial, showing favorable safety and early signs of efficacy, including significant biomarkers linked to pharmacodynamics.
Rein also provided an update on its pipeline, highlighting LTI-01, a Phase 2b-ready therapy for loculated pleural effusions, which holds Orphan Drug Designation for pleural empyema.
Brian Windsor, President and CEO, said, "The rebrand to Rein Therapeutics represents our unwavering commitment to advancing novel therapies for fibrotic diseases."
Key 2025 milestones include initiating a Phase 2 trial for LTI-03 and advancing LTI-01, which holds Fast Track Designation in the U.S. for pleural effusions.
Currently, ALRN is trading at $2.02 up by 4.66%.
For comments and feedback: editorial@rttnews.com